A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Inclusion Criteria: * Has not received any previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C * Male and female subjects, 18 to 70 years of age, inclusive * Genotype 1, chronic hepatitis C with detectable HCV RNA. * Screening laboratory values, tests, and physical exam within acceptable ranges * Able and willing to follow contraception requirements * Able to read and understand, and willing to sign the informed consent form and abide by the study restrictions. Exclusion Criteria: * Subject has any contraindications to Pegasys® or Copegus® therapy * Evidence of hepatic decompensation in cirrhotic subjects * History of organ transplant * History of, or any current medical condition which could impact the safety of the subject in participation in the study